PPT-Concomitant Antiplatelet and OAC

Tx RealWorld Practice In the US 800000 AF patients are on concomitant OAC and antiplatelet tx 1 Patients on chronic OAC with CAD are 7x more likely to receive concomitant antiplatelet tx. Antiplatelet Guidelines. Antiplatelet. Therapy for . Vascular Prevention in Patients with Peripheral Arterial Disease. Working. Group. : A. Roussin, MD, FRCP; Thomas F. Lindsay, MD, CM. , FRCSC. Objectives. Therapy for the Secondary Prevention of . Cerebrovascular. Disease. Working Group: . Ashfaq. . Shuaib. , MD, . FRCP; Philip . Teal, MD, FRCP. Canadian Cardiovascular Society . Antiplatelet Guidelines. Therapy for the Secondary Prevention of . Cerebrovascular. Disease. Working Group: . Ashfaq. . Shuaib. , MD, . FRCP; Philip . Teal, MD, FRCP. Canadian Cardiovascular Society . Antiplatelet Guidelines. Antiplatelet Guidelines. HEART FAILURE. Working Group: . Alan D. Bell, MD, CCFP; James D. . Douketis. , MD, FRCP. Objectives. Interpret . the . Canadian Cardiovascular Society Guideline . recommendations . Therapy for Secondary Prevention . Beyond One Year . Following . ACS or PCI. Working Group. : . Anil Gupta MD, FRCPC, Pierre Theroux MD, FRCPC . Canadian Cardiovascular Society Antiplatelet Guidelines. de chimiothérapie dans les cancers des . VADS: actualisation. Jean-Pierre . Pignon. , . Pierre . Blanchard, . Anne . Lee, . Laureen. . Majed. , Sophie . Marguet. , . Claire . Petit, Cécile . Landais. Minilecture. Objectives. Indications for Antiplatelet Therapy in patients with CAD and ACS. Antiplatelet Therapy in the role of primary and secondary prevention of . c. ardiovascular events. CAD & the Vulnerable Plaque. Minilecture. Objectives. Indications for Antiplatelet Therapy in patients with CAD and ACS. Antiplatelet Therapy in the role of primary and secondary prevention of . c. ardiovascular events. CAD & the Vulnerable Plaque. Anticoagulant therapy. (n = . 124). CADISS. P. rimary outcome. : . Ipsilateral . stroke or all-cause mortality . for antiplatelet vs. anticoagulation: 2. % . vs. 1%; p . = . 0.63. Any stroke: 2% vs. 1%, . 1 L ip cancer Staging evaluationCT scan for T3/T4 to assess nodalspread/bone invasion T1 : Early lesions T2: Moderately advancedlesions (2-4 cm) T3 Locally advanced�lesions (4 cm) T4a T Edit: October 2018. Content. Why treat Atrial Fibrillation (. AFib. )?. How does concomitant . AFib. therapy benefit your patients?. Who can benefit from concomitant . AFib. therapy? . Concomitant . . Katherine Belanger BS. 1. , Timothy H. Ung MD. 1. , Denise . Damek. MD. 2. , Kevin O. . Lillehei. MD. 1. , D. Ryan Ormond, MD, PhD. 1. . Department of Neurosurgery, University of Colorado School of Medicine, Aurora, CO, USA. Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are usually combined with . fulvestrant. or aromatase inhibitors for the treatment of patients with metastatic breast cancer (. mBC. ). Drug-drug interactions may affect absorption by different . intracerebral haemorrhage (ICH): extended follow-up of the. RE. start. or . ST. op. . A. ntithrombotics. . R. andomised . T. rial. (RESTART) . RESTART Collaboration. www.RESTARTtrial.org. Intracerebral haemorrhage (ICH) is associated with an increased risk of arterial ischaemic events*: pooled analysis of 4 population-based cohorts.